Toregem Biopharma Raises $5.3M to Accelerate Human Trials for Tooth Regrowth Drug

Executive Briefing

• Raises $5.3 million to fund Phase 2 clinical trials of its tooth regeneration drug in Japan
• Targets USAG-1 protein suppression to reactivate dormant tooth bud growth in patients
• Phase 1 safety trial involving adult men concluded last year with results still pending
• Aims to bring treatment to market by 2030, pending regulatory and scientific hurdles
• Experts warn drug may only work in children and could trigger unintended tooth growth